Takeda starts production of anti-cancer drug in Russia

Japanese drugmaker Takeda Pharmaceutical (TYO: 4502), together with Russia’s JSC Pharmstandard, announced the beginning of production of an anti-cancer drug, known as Adzetris (Adcetris: brentuximab vedotin), at the facilities of Pharmstandard-UfaVITA plant in the Ufa region, according to the companies.

Director general of Takeda Russia and CIS region Andrey Potapov said this is the first innovative product of the Japanese company to be manufactured in Russia, reports The Pharma Letter’s local correspondent.

Mr Potapov added that the oncological direction is a relatively new division within Takeda Russia. The company wants to make it more accessible to local consumers and, in recent years, has activated its efforts in this field.